Comprehensive analysis of the long non‑coding RNA‑associated competitive endogenous RNA network reveals novel prognostic biomarkers in Wilms' tumor

Liu,Zifeng; Zhao,Wenbo; Ren,Yuqing; Liu,Chang; Liu,Xun; Xiao,Jian

doi:10.3892/ol.2020.11500

Comprehensive analysis of the long non‑coding RNA‑associated competitive endogenous RNA network reveals novel prognostic biomarkers in Wilms' tumor

Authors:
- Zifeng Liu
- Wenbo Zhao
- Yuqing Ren
- Chang Liu
- Xun Liu
- Jian Xiao
View Affiliations

Affiliations: Department of Clinical Data Center, The Third Affiliated Hospital of Sun Yat‑Sen University, Guangzhou, Guangdong 510630, P.R. China, Department of Nephrology, The Third Affiliated Hospital of Sun Yat‑Sen University, Guangzhou, Guangdong 510630, P.R. China, Tianpeng Technology Co., Ltd, Guangzhou, Guangdong 510600, P.R. China, Department of Medical Oncology, The Sixth Affiliated Hospital of Sun Yat‑Sen University, Guangzhou, Guangdong 510655, P.R. China
Published online on: March 31, 2020 https://doi.org/10.3892/ol.2020.11500
Pages: 3731-3742
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Wilms' tumor (WT) is one of the most common types of renal carcinoma in children. The aim of the present study was to construct a competitive endogenous RNA (ceRNA) regulation network and explore novel prognostic biomarkers for WT. The expression profiles were downloaded from The Cancer Genome Atlas database to identify differentially expressed RNAs (DERNAs). Based on the interactions between microRNAs (miRNAs) and mRNAs/long non‑coding RNAs (lncRNAs), a ceRNA network was constructed. Functional enrichment analyses were subsequently conducted to explore the functions of the ceRNA‑associated DEmRNAs. Survival analysis was performed to screen for prognosis‑associated RNAs and the χ2 test was used to assess the associations between prognosis‑associated RNA expression and histology classification/clinical staging. The present study identified 1,784 lncRNAs, 114 miRNAs and 3,337 mRNAs, which were abnormally expressed in WT compared with that in normal samples. By prediction, pairing and network analysis, a ceRNA network consisting of 38 DElncRNAs, 18 DEmiRNAs and 99 DEmRNAs was established. These DEmRNAs were significantly enriched in pathways associated with the occurrence and development of WT. By combining the expression data with survival analysis, seven prognosis‑associated RNAs were identified (P<0.05). Of these seven RNAs, two (zinc finger and BTB domain containing 4; and deleted in lymphocytic leukemia 2) were significantly associated with clinical staging and histology classification. Lastly, the expression levels of the seven RNAs were verified in the Gene Expression Omnibus database. The present study revealed that 7 RNAs might be considered as novel prognostic biomarkers and potential treatment targets for therapy in WT. In addition, the ceRNA regulation network could provide novel strategies for further studies on lncRNAs and miRNAs in WT.

View Figures

View References

1	Breslow N, Olshan A, Beckwith JB and Green DM: Epidemiology of Wilms tumor. Med Pediatr Oncol. 21:172–181. 1993. View Article : Google Scholar : PubMed/NCBI
2	Brok J, Treger TD, Gooskens SL, van den Heuvel-Eibrink MM and Pritchard-Jones K: Biology and treatment of renal tumours in childhood. Eur J Cancer. 68:179–195. 2016. View Article : Google Scholar : PubMed/NCBI
3	Chu A, Heck JE, Ribeiro KB, Brennan P, Boffetta P, Buffler P and Hung RJ: Wilms' tumour: A systematic review of risk factors and meta-analysis. Paediatr Perinat Epidemiol. 24:449–469. 2010. View Article : Google Scholar : PubMed/NCBI
4	Pastore G, Znaor A, Spreafico F, Graf N, Pritchard-Jones K and Steliarova-Foucher E: Malignant renal tumours incidence and survival in European children (1978–1997): Report from the Automated Childhood Cancer Information System project. Eur J Cancer. 42:2103–2114. 2006. View Article : Google Scholar : PubMed/NCBI
5	Magnani C, Pastore G, Coebergh JW, Viscomi S, Spix C and Steliarova-Foucher E: Trends in survival after childhood cancer in Europe, 1978-1997: Report from the Automated Childhood Cancer Information System project (ACCIS). Eur J Cancer. 42:1981–2005. 2006. View Article : Google Scholar : PubMed/NCBI
6	Geller JI: Current standards of care and future directions for ‘high-risk’ pediatric renal tumors: Anaplastic Wilms tumor and Rhabdoid tumor. Urol Oncol. 34:50–56. 2016. View Article : Google Scholar : PubMed/NCBI
7	Spreafico F, Pritchard Jones K, Malogolowkin MH, Bergeron C, Hale J, de Kraker J, Dallorso S, Acha T, de Camargo B, Dome JS, et al: Treatment of relapsed Wilms tumors: Lessons learned. Expert Rev Anticancer Ther. 9:1807–1815. 2009. View Article : Google Scholar : PubMed/NCBI
8	Zhu S, Fu W, Zhang L, Fu K, Hu J, Jia W and Liu G: LINC00473 antagonizes the tumour suppressor miR-195 to mediate the pathogenesis of Wilms tumour via IKKα. Cell Prolif. Nov 20–2017.(Epub ahead of print). doi: https://doi.org/10.1111/cpr.12416.
9	Yu X, Li Z, Chan MT and Wu WK: The roles of microRNAs in Wilms' tumors. Tumour Biol. 37:1445–1450. 2016. View Article : Google Scholar : PubMed/NCBI
10	Su L, Wu A, Zhang W and Kong X: Silencing long non-coding RNA SNHG6 restrains proliferation, migration and invasion of Wilms' tumour cell lines by regulating miR-15a. Artif Cells Nanomed Biotechnol. 47:2670–2677. 2019. View Article : Google Scholar : PubMed/NCBI
11	Ponting CP, Oliver PL and Reik W: Evolution and functions of long noncoding RNAs. Cell. 136:629–641. 2009. View Article : Google Scholar : PubMed/NCBI
12	Muers M: RNA: Genome-wide views of long non-coding RNAs. Nat Rev Genet. 12:742–743. 2011. View Article : Google Scholar : PubMed/NCBI
13	Ye W, Lv Q, Wong CK, Hu S, Fu C, Hua Z, Cai G, Li G, Yang BB and Zhang Y: The effect of central loops in miRNA:MRE duplexes on the efficiency of miRNA-mediated gene regulation. PLoS One. 3:e17192008. View Article : Google Scholar : PubMed/NCBI
14	Cao X, Liu D, Yan X, Zhang Y, Yuan L, Zhang T, Fu M, Zhou Y and Wang J: Stat3 inhibits WTX expression through up-regulation of microRNA-370 in Wilms tumor. FEBS Lett. 587:639–644. 2013. View Article : Google Scholar : PubMed/NCBI
15	Jiang X and Li H: MiR-1180-5p regulates apoptosis of Wilms' tumor by targeting p73. OncoTargets Ther. 11:823–831. 2018. View Article : Google Scholar
16	Cui M, Liu W, Zhang L, Guo F, Liu Y, Chen F, Liu T, Ma R and Wu R: Over-expression of miR-21 and lower PTEN levels in Wilms' tumor with aggressive behavior. Tohoku J Exp Med. 242:43–52. 2017. View Article : Google Scholar : PubMed/NCBI
17	Liu GL, Yang HJ, Liu B and Liu T: Effects of MicroRNA-19b on the proliferation, apoptosis, and migration of Wilms' tumor cells via the PTEN/PI3K/AKT signaling pathway. J Cell Biochem. 118:3424–3434. 2017. View Article : Google Scholar : PubMed/NCBI
18	Okamoto K, Morison IM, Taniguchi T and Reeve AE: Epigenetic changes at the insulin-like growth factor II/H19 locus in developing kidney is an early event in Wilms tumorigenesis. Proc Natl Acad Sci USA. 94:5367–5371. 1997. View Article : Google Scholar : PubMed/NCBI
19	Zhang J, Hou T, Qi X, Wang J and Sun X: SOX21-AS1 is associated with clinical stage and regulates cell proliferation in nephroblastoma. Biosci Rep. May 17–2019.(Epub ahead of print). doi: 10.1042/BSR20190602.
20	Peng Y and Croce CM: The role of MicroRNAs in human cancer. Signal Transduct Target Ther. 1:150042016. View Article : Google Scholar : PubMed/NCBI
21	Su H, Wang X, Song J, Wang Y, Zhao Y and Meng J: MicroRNA-539 inhibits the progression of Wilms' tumor through downregulation of JAG1 and Notch1/3. Cancer Biomark. 24:125–133. 2019. View Article : Google Scholar : PubMed/NCBI
22	Salmena L, Poliseno L, Tay Y, Kats L and Pandolfi PP: A ceRNA hypothesis: The Rosetta Stone of a hidden RNA language? Cell. 146:353–358. 2011. View Article : Google Scholar : PubMed/NCBI
23	Liu H, Zhang Z, Wu N, Guo H, Zhang H, Fan D, Nie Y and Liu Y: Integrative analysis of dysregulated lncRNA-associated ceRNA network reveals functional lncRNAs in gastric cancer. Genes (Basel). Jun 18–2018.(Epub ahead of print). doi: 10.3390/genes9060303.
24	Arun K, Arunkumar G, Bennet D, Chandramohan SM, Murugan AK and Munirajan AK: Comprehensive analysis of aberrantly expressed lncRNAs and construction of ceRNA network in gastric cancer. Oncotarget. 9:18386–18399. 2018. View Article : Google Scholar : PubMed/NCBI
25	Gao C, Li H, Zhuang J, Zhang H, Wang K, Yang J, Liu C, Liu L, Zhou C and Sun C: The construction and analysis of ceRNA networks in invasive breast cancer: A study based on The Cancer Genome Atlas. Cancer Manag Res. 11:1–11. 2018. View Article : Google Scholar : PubMed/NCBI
26	Yan Y, Yu J, Liu H, Guo S, Zhang Y, Ye Y, Xu L and Ming L: Construction of a long non-coding RNA-associated ceRNA network reveals potential prognostic lncRNA biomarkers in hepatocellular carcinoma. Pathol Res Pract. 214:2031–2038. 2018. View Article : Google Scholar : PubMed/NCBI
27	Yuan W, Li X, Liu L, Wei C, Sun D, Peng S and Jiang L: Comprehensive analysis of lncRNA-associated ceRNA network in colorectal cancer. Biochem Biophys Res Commun. 508:374–379. 2019. View Article : Google Scholar : PubMed/NCBI
28	Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C and Stuart JM; Cancer Genome Atlas Research Network, : The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 45:1113–1120. 2013. View Article : Google Scholar : PubMed/NCBI
29	Aken BL, Ayling S, Barrell D, Clarke L, Curwen V, Fairley S, Fernandez Banet J, Billis K, García Girón C, Hourlier T, et al: The Ensembl gene annotation system. Database (Oxford). Jun 23–2016.(Epub ahead of print). doi: 10.1093/database/baw093. View Article : Google Scholar : PubMed/NCBI
30	Robinson MD, McCarthy DJ and Smyth GK: edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 26:139–140. 2010. View Article : Google Scholar : PubMed/NCBI
31	Jeggari A, Marks DS and Larsson E: miRcode: A map of putative microRNA target sites in the long non-coding transcriptome. Bioinformatics. 28:2062–2063. 2012. View Article : Google Scholar : PubMed/NCBI
32	Wong N and Wang X: miRDB: An online resource for microRNA target prediction and functional annotations. Nucleic Acids Res. 43:D146–D152. 2015. View Article : Google Scholar : PubMed/NCBI
33	Hsu SD, Lin FM, Wu WY, Liang C, Huang WC, Chan WL, Tsai WT, Chen GZ, Lee CJ, Chiu CM, et al: miRTarBase: A database curates experimentally validated microRNA-target interactions. Nucleic Acids Res. 39 (Suppl 1):D163–D169. 2011. View Article : Google Scholar : PubMed/NCBI
34	Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 120:15–20. 2005. View Article : Google Scholar : PubMed/NCBI
35	Smoot ME, Ono K, Ruscheinski J, Wang PL and Ideker T: Cytoscape 2.8: New features for data integration and network visualization. Bioinformatics. 27:431–432. 2011. View Article : Google Scholar : PubMed/NCBI
36	Blake JA and Harris MA: The Gene Ontology (GO) project: Structured vocabularies for molecular biology and their application to genome and expression analysis. Curr Protoc Bioinformatics. Sep 1–2008.(Epub ahead of print). doi: https://doi.org/10.1002/0471250953.bi0702s23. View Article : Google Scholar : PubMed/NCBI
37	Kanehisa M and Goto S: KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28:27–30. 2000. View Article : Google Scholar : PubMed/NCBI
38	Yu G, Wang LG, Han Y and He QY: clusterProfiler: An R package for comparing biological themes among gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
39	Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P, et al: STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 47:D607–D613. 2019. View Article : Google Scholar : PubMed/NCBI
40	Bland JM and Altman DG: The logrank test. BMJ. 328:10732004. View Article : Google Scholar : PubMed/NCBI
41	Ludwig N, Werner TV, Backes C, Trampert P, Gessler M, Keller A, Lenhof HP, Graf N and Meese E: Combining miRNA and mRNA Expression Profiles in Wilms Tumor Subtypes. Int J Mol Sci. 17:4752016. View Article : Google Scholar : PubMed/NCBI
42	Liu M, Roth A, Yu M, Morris R, Bersani F, Rivera MN, Lu J, Shioda T, Vasudevan S, Ramaswamy S, et al: The IGF2 intronic miR-483 selectively enhances transcription from IGF2 fetal promoters and enhances tumorigenesis. Genes Dev. 27:2543–2548. 2013. View Article : Google Scholar : PubMed/NCBI
43	Barabási AL and Oltvai ZN: Network biology: Understanding the cell's functional organization. Nat Rev Genet. 5:101–113. 2004. View Article : Google Scholar : PubMed/NCBI
44	Tian F, Yourek G, Shi X and Yang Y: The development of Wilms tumor: From WT1 and microRNA to animal models. Biochim Biophys Acta. 1846:180–187. 2014.PubMed/NCBI
45	Qi X, Zhang DH, Wu N, Xiao JH, Wang X and Ma W: ceRNA in cancer: Possible functions and clinical implications. J Med Genet. 52:710–718. 2015. View Article : Google Scholar : PubMed/NCBI
46	Chan JJ and Tay Y: Noncoding RNA:RNA Regulatory Networks in Cancer. Int J Mol Sci. 19:E13102018. View Article : Google Scholar : PubMed/NCBI
47	Tay Y, Rinn J and Pandolfi PP: The multilayered complexity of ceRNA crosstalk and competition. Nature. 505:344–352. 2014. View Article : Google Scholar : PubMed/NCBI
48	Klein U, Lia M, Crespo M, Siegel R, Shen Q, Mo T, Ambesi-Impiombato A, Califano A, Migliazza A, Bhagat G, et al: The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell. 17:28–40. 2010. View Article : Google Scholar : PubMed/NCBI
49	Lerner M, Harada M, Lovén J, Castro J, Davis Z, Oscier D, Henriksson M, Sangfelt O, Grandér D and Corcoran MM: DLEU2, frequently deleted in malignancy, functions as a critical host gene of the cell cycle inhibitory microRNAs miR-15a and miR-16-1. Exp Cell Res. 315:2941–2952. 2009. View Article : Google Scholar : PubMed/NCBI
50	Xie ZZ, Xiao ZC, Song YX, Li W and Tan GL: Long non-coding RNA Dleu2 affects proliferation, migration and invasion ability of laryngeal carcinoma cells through triggering miR-16-1 pathway. Eur Rev Med Pharmacol Sci. 22:1963–1970. 2018.PubMed/NCBI
51	Tan W, Liu B, Qu S, Liang G, Luo W and Gong C: MicroRNAs and cancer: Key paradigms in molecular therapy. Oncol Lett. 15:2735–2742. 2018.PubMed/NCBI
52	Ludwig N, Nourkami-Tutdibi N, Backes C, Lenhof HP, Graf N, Keller A and Meese E: Circulating serum miRNAs as potential biomarkers for nephroblastoma. Pediatr Blood Cancer. 62:1360–1367. 2015. View Article : Google Scholar : PubMed/NCBI
53	Mokutani Y, Uemura M, Munakata K, Okuzaki D, Haraguchi N, Takahashi H, Nishimura J, Hata T, Murata K, Takemasa I, et al: Down-Regulation of microRNA-132 is Associated with Poor Prognosis of Colorectal Cancer. Ann Surg Oncol. 23 (Suppl 5):599–608. 2016. View Article : Google Scholar : PubMed/NCBI
54	Park JK, Henry JC, Jiang J, Esau C, Gusev Y, Lerner MR, Postier RG, Brackett DJ and Schmittgen TD: miR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor. Biochem Biophys Res Commun. 406:518–523. 2011. View Article : Google Scholar : PubMed/NCBI
55	Tian H, Hou L, Xiong YM, Huang JX, Zhang WH, Pan YY and Song XR: miR-132 targeting E2F5 suppresses cell proliferation, invasion, migration in ovarian cancer cells. Am J Transl Res. 8:1492–1501. 2016.PubMed/NCBI
56	Zhang X, Tang W, Li R, He R, Gan T, Luo Y, Chen G and Rong M: Downregulation of microRNA-132 indicates progression in hepatocellular carcinoma. Exp Ther Med. 12:2095–2101. 2016. View Article : Google Scholar : PubMed/NCBI
57	Filion GJ, Zhenilo S, Salozhin S, Yamada D, Prokhortchouk E and Defossez PA: A family of human zinc finger proteins that bind methylated DNA and repress transcription. Mol Cell Biol. 26:169–181. 2006. View Article : Google Scholar : PubMed/NCBI
58	Kim K, Chadalapaka G, Lee SO, Yamada D, Sastre-Garau X, Defossez PA, Park YY, Lee JS and Safe S: Identification of oncogenic microRNA-17-92/ZBTB4/specificity protein axis in breast cancer. Oncogene. 31:1034–1044. 2012. View Article : Google Scholar : PubMed/NCBI
59	Ross-Adams H, Lamb AD, Dunning MJ, Halim S, Lindberg J, Massie CM, Egevad LA, Russell R, Ramos-Montoya A, Vowler SL, et al CamCaP Study Group, : Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study. EBioMedicine. 2:1133–1144. 2015. View Article : Google Scholar : PubMed/NCBI
60	Yu Y, Shang R, Chen Y, Li J, Liang Z, Hu J, Liu K and Chen C: Tumor suppressive ZBTB4 inhibits cell growth by regulating cell cycle progression and apoptosis in Ewing sarcoma. Biomed Pharmacother. 100:108–115. 2018. View Article : Google Scholar : PubMed/NCBI
61	Roussel-Gervais A, Naciri I, Kirsh O, Kasprzyk L, Velasco G, Grillo G, Dubus P and Defossez PA: Loss of the Methyl-CpG-Binding Protein ZBTB4 Alters Mitotic Checkpoint, Increases Aneuploidy, and Promotes Tumorigenesis. Cancer Res. 77:62–73. 2017. View Article : Google Scholar : PubMed/NCBI
62	Tao F, Tian X, Ruan S, Shen M and Zhang Z: miR-211 sponges lncRNA MALAT1 to suppress tumor growth and progression through inhibiting PHF19 in ovarian carcinoma. FASEB J. Jun 6–2018.(Epub ahead of print). doi: 10.1096/fj.201800495RR. View Article : Google Scholar